Cargando…

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals

INTRODUCTION: Fixed-dose combinations (FDC) contain two or more active ingredients. The effective patent and exclusivity life of FDC compared to single active ingredient has not been assessed. OBJECTIVES: Trends in FDA approved FDC in the period 1980–2012 and time lag between approval of FDC and sin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hao, Jing, Rodriguez-Monguio, Rosa, Seoane-Vazquez, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607470/ https://www.ncbi.nlm.nih.gov/pubmed/26469277 http://dx.doi.org/10.1371/journal.pone.0140708

Ejemplares similares

A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas
por: Rodriguez-Monguio, Rosa, et al.
Publicado: (2023)

The Development of Innovative Dosage Forms of the Fixed-Dose Combination of Active Pharmaceutical Ingredients
por: Janczura, Magdalena, et al.
Publicado: (2022)

Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies
por: Nguyen, Diane, et al.
Publicado: (2013)

Disentangling the Cost of Orphan Drugs Marketed in the United States
por: Althobaiti, Hana, et al.
Publicado: (2023)

Patent and Marketing Exclusivities 101 for Drug Developers
por: Oronsky, Bryan, et al.
Publicado: (2023)

NIH funding for patents that contribute to market exclusivity of drugs approved 2010–2019 and the public interest protections of Bayh-Dole
por: Ledley, Fred D., et al.
Publicado: (2023)

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication
por: Balkhi, Bander, et al.
Publicado: (2018)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Innovation and competition in advanced therapy medicinal products
por: Seoane‐Vazquez, Enrique, et al.
Publicado: (2019)

Predictors of shortages of opioid analgesics in the US: Are the characteristics of the drug company the missing puzzle piece?
por: Rodriguez-Monguio, Rosa, et al.
Publicado: (2021)

Regulatory requirements for marketing fixed dose combinations
por: Jayasheel, B. G.
Publicado: (2010)

Dynamics of price competition in Italian pharmaceutical off-patent market
por: Perna, Serena, et al.
Publicado: (2022)

Drug utilization and cost in a Medicaid population: A simulation study of community vs. mail order pharmacy
por: Valluri, Satish, et al.
Publicado: (2007)

Incentives for orphan drug research and development in the United States
por: Seoane-Vazquez, Enrique, et al.
Publicado: (2008)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
por: Olsen, Anders, et al.
Publicado: (2023)

Effect of free trade agreements on pharmaceutical market competition: The case of the 2009 US-Peru free trade agreement and its implementation as national drug policy
por: Araujo, Lita, et al.
Publicado: (2021)

Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients
por: Kovács, Bence, et al.
Publicado: (2021)

Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase
por: Brewitz, Lennart, et al.
Publicado: (2020)

Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
por: Rodriguez-Monguio, R., et al.
Publicado: (2017)

Identification of US-pharmaceutical patents expiring between 2018 and 2022 and their effect on the Brazilian domestic market
por: Paes, Thalita D.M., et al.
Publicado: (2020)

Multicomponent Reactions for the Synthesis of Active Pharmaceutical Ingredients
por: Cores, Ángel, et al.
Publicado: (2022)

Chemical Engineering in the Pharmaceutical Industry, Active Pharmaceutical Ingredients
por: Ende, David
Publicado: (2019)

Digital pills for the remote monitoring of medication intake: a stakeholder analysis and assessment of marketing approval and patent granting policies
por: Sideri, Katerina, et al.
Publicado: (2022)

Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea
por: Choi, Nahye, et al.
Publicado: (2022)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

Parenteral Ready-to-Use Fixed-Dose Combinations Including NSAIDs with Paracetamol or Metamizole for Multimodal Analgesia—Approved Products and Challenges
por: Silva, Fernando, et al.
Publicado: (2023)

New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine
por: Wang, Nana, et al.
Publicado: (2023)

Regulatory enforcement of the marketing of fixed-dose combinations in India: a case study of systemic antibiotics
por: Brhlikova, Petra, et al.
Publicado: (2023)

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
por: De Groot, Anne S., et al.
Publicado: (2013)

Structure of the active pharmaceutical ingredient bismuth subsalicylate
por: Svensson Grape, Erik, et al.
Publicado: (2022)

Pharmaceutical patenting in the European Union: reform or riddance
por: Garattini, Livio, et al.
Publicado: (2021)

Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(®) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
por: Choi, YoonJung, et al.
Publicado: (2015)

Understanding flow chemistry for the production of active pharmaceutical ingredients
por: Burange, Anand S., et al.
Publicado: (2022)

Efficient Screening of Coformers for Active Pharmaceutical Ingredient Cocrystallization
por: Sugden, Isaac J., et al.
Publicado: (2022)

Marine Ingredients for Sensitive Skin: Market Overview
por: Ferreira, Marta Salvador, et al.
Publicado: (2021)

An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile
por: Abud, María José, et al.
Publicado: (2015)

Perverse Results from Pharmaceutical Patents in the United States
por: Grimes, Warren
Publicado: (2021)

Patent and Exclusivity Status of Essential Medicines for Non-Communicable Disease
por: Mackey, Tim K., et al.
Publicado: (2012)

PIN58 The U.S. International Trade of Medical Products in the COVID-19 Era
por: Preciado, S.M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2vudu1g5m0emio4lhb09uq2o4t